2018 American Transplant Congress
Clinical Outcomes of Conversion from Calcineurin Inhibitor to Belatacept-Based Immunosuppression in Highly Sensitized Kidney Transplant Recipients
Cedars Sinai Medical Center, Los Angeles.
Introduction:Efficacy of belatacept when converted from calcineurin inhibitors (CNI) in high immunologic risk patients has not been established. We examined the impact of HLA-sensitization on…2018 American Transplant Congress
Presence of Chronic Vascular Lesions on Allograft Biopsy is Associated with Greater Improvement in Renal Function after Conversion from Tacrolimus to Belatacept
Background: Conversion from tacrolimus to belatacept has been shown to be beneficial for an increasing number of kidney transplant (KT) patients. However, predicting factors for…2018 American Transplant Congress
Precision Medicine for Determining the Efficacy of a Novel Belatacept Regimen
Transplant Nephrology, UCSF, San Francisco, CA.
IntroBelatacept is increasingly used as maintenance immunosuppression to improve long term outcomes in kidney transplant. Since acute rejection in patients on belatacept have been noted…2018 American Transplant Congress
Cognition after Belatacept Conversion
Yale University, New Haven, CT.
Intro: Kidney Transplant Recipients (KTRs) taking calcineurin inhibitors (CNIs) can experience varying drug toxicities. Less well studied compared to the metabolic consequences, many patients report…2018 American Transplant Congress
Metabolic Therapy as a Platform for CTLA4Ig Costimulation Blockade in Preventing Allograft Rejection
The backbone of current immunosuppression regimens remains calcineurin inhibitors (CNI) in association with steroids, mycophenolate mofetil or mTOR inhibitors. However, their long-term administration is associated…2018 American Transplant Congress
Urinary CXCL9 Monitoring to Accompany a Safe CNI-to-Belatacept Conversion in Kidney Transplant Patients
Background: Converting renal transplant recipients from CNI to belatacept immunosuppression has been proposed as a strategy to limit nephrotoxicity, but it is associated with an…2018 American Transplant Congress
Enrichment of Endogenous Donor-Reactive Tregs in the Spleen and Graft during Transplantation Tolerance is the Result of Treg Proliferation and Conversion from Tconv
Surgery and Medicine, University of Chicago, Chicago, IL.
Foxp3+ regulatory T cells (Tregs) are critical mediators of immune tolerance and are absolutely required for allograft tolerance in animal models. In addition, clinical trials…2018 American Transplant Congress
The Infusion with a Difference: Patient Experiences with Belatacept
Yale University, New Haven, CT.
Introduction: The results of the BENEFIT trial led to the FDA approval of the novel anti-rejection agent belatacept (bela) in 2011. In addition to its…2018 American Transplant Congress
Inhibition of IL-1R1 Signaling Delays Costimulation Blockade–Resistant Allograft Rejection by Preventing CD8 TEM Expansion
Department of Surgery, Emory University, Atlanta, GA.
The clinical utilization of Costimulaiton Blockade (CoB) led to improved long-term patient outcomes, but wider adoption of is hampered by increased rates of acute cellular…2018 American Transplant Congress
Circulating T Follicular Helper Cells Expand Following Transplantation and Exhibit a CD44hi Phenotype That Correlates with Peak Germinal Center Alloreactivity
Emory Transplant Center, Atlanta.
It is increasingly well-recognized that donor-specific antibodies (DSA) play a significant role in the development of chronic rejection and fibrosis that contribute to late renal…
- « Previous Page
- 1
- …
- 15
- 16
- 17
- 18
- 19
- …
- 30
- Next Page »